Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse

Leukemia
S-J ChoiK-H Lee

Abstract

For patients with acute myeloid leukemia (AML) relapsed after allogeneic bone marrow transplantation (BMT), donor leukocyte infusion (DLI) as sole therapy has very limited efficacy. We tested the effects of cytoreductive chemotherapy, followed immediately by G-CSF-primed DLI (chemotherapy followed by DLI, Chemo-DLI), in 16 AML patients who relapsed after allogeneic BMT. In all, 10 of these patients achieved complete remission (CR), four of whom remain alive in CR at a median follow-up of 1488 days after DLI. The 2-year overall survival (OS) for the entire cohort was 31%. The 1-year OS for patients with post-BMT remission of 6 months or longer was 55%, compared with 0% for patients with post-BMT remission of less than 6 months, making post-BMT remission duration the only significant prognostic factor for OS (P=0.015). These findings suggest that Chemo-DLI could induce durable remissions in a proportion of relapsed AML patients with relatively long post-BMT remission duration. All five patients who relapsed after achieving CR with Chemo-DLI relapsed at extramedullary sites in the presence of continuous bone marrow remission, suggesting uneven graft-versus-leukemia effects in different parts of the body. Although our data should b...Continue Reading

References

Jan 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J MortimerE D Thomas
May 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J FrickT Anderson
Aug 1, 1980·The American Journal of Medicine·H M ShulmanE D Thomas
Feb 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P RadichJ A Hansen
Apr 5, 1996·Science·E C Butcher, L J Picker
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R H CollinsJ Nemunaitis
Aug 28, 1999·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·D L PorterJ H Antin
Aug 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A BosiUNKNOWN Acute Leukemia Working Party of the European Blood and Marrow Transplant Group
Jan 12, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John E LevineRobert H Collins
Apr 23, 2004·Experimental Hematology·Elisabet NadalFrancesco Dazzi

❮ Previous
Next ❯

Citations

May 13, 2005·Cancer Immunology, Immunotherapy : CII·Marie RobinRose-Ann Padua
Jul 28, 2007·Nature Clinical Practice. Oncology·Taofeek OwonikokoAnastasios Raptis
Oct 7, 2005·International Journal of Hematology·Guillermo J Ruiz-ArgüellesCésar H Gutiérrez-Aguirrec
Jul 12, 2008·Hematology·Sevgi Kalayoglu-BesisikMahmut Carin
Feb 22, 2014·Leukemia & Lymphoma·Kenji MatsumotoHeiwa Kanamori
May 24, 2012·Leukemia & Lymphoma·Travis WilliamsSri G Yarlagadda
Oct 27, 2006·Leukemia & Lymphoma·Isabel Cunningham
Nov 10, 2009·Expert Review of Molecular Diagnostics·Egle GineikieneLaimonas Griskevicius
Jul 27, 2011·Expert Review of Clinical Immunology·Aleksandra Petrovic, Gregory Hale
Jun 6, 2014·Cancer Investigation·Karim ArnaoutImad A Tabbara
Sep 9, 2009·British Journal of Haematology·Olle RingdénMichael Uhlin
Jul 20, 2011·Experimental Hematology·Ji-Young LimChang-Ki Min
Sep 16, 2008·Best Practice & Research. Clinical Haematology·Robert J Soiffer
Feb 6, 2007·British Journal of Haematology·Jonas AbrahamssonUNKNOWN Nordic Society for Paediatric Haematology and Oncology (NOPHO)
Feb 29, 2008·American Journal of Hematology·Osamu ImatakiToshihiko Ishida
Sep 26, 2006·Best Practice & Research. Clinical Haematology·David L Porter, Joseph H Antin
Dec 17, 2005·Seminars in Nuclear Medicine·Phillip H KuoDavid W Cheng
Apr 8, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ling GeXiaowen Tang
Mar 26, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Merav BarMary E D Flowers
May 29, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Satoshi YoshiharaHiroyasu Ogawa
Dec 14, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Erica D WarlickJeffrey S Miller
Sep 25, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Marco MielcarekPaul J Martin
Jun 15, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Darius SairafiJonas Mattsson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.